Drug Trial Radar · NCT06892379
A Study of HS-20110 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
631
Planned (sponsor's estimate)
Start
Feb 26, 2025
Primary completion
Dec 31, 2026
Study completion Mar 3, 2029
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- Hoffmann-La Roche
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Conditions
- Solid Tumors
Interventions
HS-20110Drug
HS-20110 will be administered by intravenous infusion in 21 day or 28 day dosing cycles.
HS-20110Drug
The recommended dose from the dose-escalation stage and other potential doses will be further explored. HS-20110 for will be administered by intravenous infusion at selected dose levels, administered in 21 day or 28 day dosing cycles.
HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.Drug
HS-20110 will be administered by intravenous infusion on a Q2W schedule at the dose level determined by the SRC in combination with the standard-of-care regimen in 28 days dosing cycles.
HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.Drug
HS-20110 will be administered by intravenous infusion at selected dose levels and schedules in combination with the standard-of-care regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) or maximum applicable dose (MAD)Time frame: From day 1 to one months after the last dose in Phase 1a
- Objective response rate (ORR) as per RECIST v1.1Time frame: From screening to 2 months after the last dose
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
BRCR Medical Center INC
Tamarac, Florida · Recruiting
Winship Cancer Institute
Atlanta, Georgia · Recruiting
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana · Recruiting
Carolina BioOncology Institute
Huntersville, North Carolina · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
SUN YAT-SEN University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.